Boston Biomedical is a company that specializes in oncology drug research. Its programs are focused on agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company develops a pipeline of agents to treat solid tumors and hematologic malignancies. Boston Biomedical merged with Tolero Pharmaceuticals to form Sumitomo Dainippon Pharma Oncology.